BBIO Earnings

BBIO reported its earnings on 2026-02-24, showcasing a revenue of 154.18M against an estimate of 150.47M, resulting in a 2.46% surprise. The EPS was -1, surpassing the expected -0.75 by -33.33%. The stock experienced a -2.59% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following BBIO's earnings announcement on 2026-02-24, the stock price moved by -2.59% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, BBIO's stock price tends to shift by an average of -4.07% in the 10 days leading up to earnings and -3.42% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate BBIO's annual revenue to reach 167.54M, while the EPS is projected at -0.65. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -0.02% over the past three months, indicating analyst expectation in the company's performance.

The correlation between BBIO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -0.02%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BBIO's stock price typically moves by -4.07% in the 10 days before its earnings and -3.42% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.65 and revenue of 167.54M.

The earnings call showed strong financial performance with significant revenue growth and promising drug trials. Attruby's market share is expanding, and the company has a solid cash position. Despite increased operating expenses, the focus on organic growth and potential shareholder returns is favorable. The Q&A highlighted management's confidence in sustained growth and strategic use of cash. The market cap suggests a moderate reaction, leading to a positive outlook for the stock price.